SHANGHAI, China and SUZHOU, China and GERMANTOWN, MD., Oct. 20, 2022 – Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight preclinical studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody 欧洲杯买球网棋牌, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager 欧洲杯买球网赞助.
Poster presentations:
1.
Title: ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models
Abstract No.: 426
Date and time: 11/11/2022, 9:00 am - 9:00 pm (EST)
2.
Title: 欧洲杯买球网棋牌, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation
Abstract No.: 1062
Date and time: 11/11/2022, 9:00 am - 9:00 pm (EST)
3.
Title: Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity
Abstract No.: 793
Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST)
4.
Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity
Abstract No.: 1211
Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST)
5.
Title: SIGLEC15 induces monocyte apoptosis and an SIGLEC15 antibody ES012 reverses myeloid cells driven immunosuppression
Abstract No.: 1401
Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST)
Corporate Communications:
PR@elpiscience.com
Partnering:
BD@elpiscience.com
